%0 Journal Article
%T 心力康丸联合西医治疗射血分数下降型慢性心力衰竭的临床观察
Clinical Observation of the Combined Treatment of Xinlikang Pills and Western Medicine for Chronic Heart Failure with Reduced Ejection Fraction
%A 党门萌
%A 周谷城
%A 王意
%A 杨红艳
%J Advances in Clinical Medicine
%P 894-900
%@ 2161-8720
%D 2025
%I Hans Publishing
%R 10.12677/acm.2025.151120
%X 目的：探究心力康丸治疗射血分数下降型慢性心力衰竭的临床疗效及安全性。方法：选取2023年9月~2024年12月在湖北省十堰市中医医院门诊就诊及住院部住院的符合先前制订的纳入标准和排除标准198名心力衰竭的患者。按随机双盲法进行分组，每组各99例。对照组给予安慰剂进行治疗，试验组给予心力康丸进行治疗，干预时间为3个月。测定两组治疗前后6分钟步行距离(6MWD)、中医证候评分、NT-proBNP。结果：治疗前后6分钟步行距离(6MWD)、中医证候评分、NT-proBNP比较，试验组均优于对照组(P < 0.05)。结论：心力康丸治疗射血分数下降型慢性心力衰竭的疗效显著，值得临床推广并使用。
Objective: To explore the clinical efficacy and safety of Xinlikang pills in the treatment of chronic heart failure with reduced ejection fraction. Methods: A total of 198 patients with heart failure, who met the predefined inclusion and exclusion criteria and were admitted to the outpatient and inpatient departments of Hubei Shiyan Hospital of Traditional Chinese Medicine from September 2023 to December 2024, were selected. They were randomly and doubly blinded divided into two groups, with 99 patients in each group. The control group received a placebo, while the experimental group received Xinlikang pills. The intervention period lasted for 3 months. The 6-minute walk distance (6MWD), Traditional Chinese Medicine (TCM) syndrome score, and NT-proBNP were measured before and after treatment in both groups. Results: Comparison of the 6MWD, TCM syndrome score, and NT-proBNP before and after treatment showed that the experimental group performed better than the control group (P < 0.05). Conclusion: Xinlikang pills demonstrate significant efficacy in the treatment of chronic heart failure with reduced ejection fraction and are worthy of clinical promotion and use.
%K 心力衰竭，
%K 心肺气虚证，
%K 血瘀水停证，
%K 心力康丸
Heart Failure
%K Cardiopulmonary Qi Deficiency Syndrome
%K Blood Stasis and Water Stop Syndrome
%K Xinlikang Pill
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=105393